Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 63 Days Payable is 73.35 as of Mar. 2026, which is 19% below its 10-year median of 90.25. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.10 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 927 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks worse than 55.45% on this metric.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's Days Payable falls into.
Wakamoto Pharmaceutical Co Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Wakamoto Pharmaceutical Co (TSE:4512) has a Days Payable of 73.35 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is 19% below median its historical median of 90.25. Over the past decade, Wakamoto Pharmaceutical Co's Days Payable has ranged from 75.13 to 106.50. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #514 out of 927 companies in the Drug Manufacturers industry, placing it in the top 55.4%.
Is Wakamoto Pharmaceutical Co's Days Payable too high?
Wakamoto Pharmaceutical Co's current Days Payable of 73.35 is 19% below median its 10-year median of 90.25. Over the past 10 years, this metric has ranged from a low of 75.13 to a high of 106.50. The Drug Manufacturers industry median Days Payable is 90.38. Wakamoto Pharmaceutical Co's value of 73.35 is 18.8% below this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #514 out of 927 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #514 out of 927 companies for Days Payable. This places Wakamoto Pharmaceutical Co in the lower half of its industry. The industry median Days Payable is 90.38. Wakamoto Pharmaceutical Co's value of 73.35 is 18.8% below this benchmark. Historically, Wakamoto Pharmaceutical Co's own Days Payable has ranged from 75.13 to 106.50 over the past decade. While the company's 10-year median is 90.25 vs. the industry median of 90.38, Wakamoto Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current Days Payable of 73.35 is 18.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current Days Payable is 73.35, which is 19% below median its own 10-year median of 90.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.10, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current Days Payable is 73.35, which is 19% below median its 10-year median of 90.25 and 18.8% below the Drug Manufacturers industry median of 90.38. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Days Payable is 73.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.10.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
Days Payable: 73.35 (19% below median its 10-year median of 90.25)
GF Value™: 円319.10 vs. price of 円278.00 (12.9% below fair value)
Industry Position: 18.8% below the Drug Manufacturers median (#514 of 927)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
